Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Investors boost stakes in Illumina, which beat earnings estimates, driving its stock up.
Several institutional investors have increased their stakes in Illumina, Inc., a life sciences company.
Vinva Investment Management Ltd bought 6,600 shares, while others like Rockefeller Capital Management and Maverick Capital Ltd adjusted their holdings.
Illumina recently reported earnings of $1.14 per share, beating estimates by $0.26.
Analysts have given positive ratings, with a consensus "Moderate Buy" and a target price of $164.00.
6 Articles
Los inversores aumentan las apuestas en Illumina, lo que supera las estimaciones de ingresos, elevando sus existencias.